Surgical menopause occurs when both ovaries are removed (bilateral oophorectomy), most commonly as part of a hysterectomy, a risk-reducing procedure in women with BRCA mutations, or treatment for endometriosis. The result is an immediate and complete cessation of ovarian estrogen, progesterone, and testosterone production, rather than the gradual years-long decline of natural menopause.

This distinction matters clinically. The research on surgical menopause is distinct from research on natural menopause, and the risk-benefit calculation for HRT is different in ways that are not always communicated clearly.

How Surgical Menopause Differs From Natural Menopause

In natural menopause, estrogen declines over several years before the final menstrual period. The body has time to adapt. By postmenopause, some physiological adjustment has occurred.

In surgical menopause (particularly when performed on premenopausal women), the ovaries are removed and estrogen falls to postmenopausal levels within days. There is no transition period. This abrupt withdrawal produces vasomotor symptoms that are often more severe than those of natural menopause, and long-term health risks that are substantially elevated compared to natural menopause at the same age.[1]

The Long-Term Risk Profile

Research consistently finds higher rates of adverse outcomes in women who had oophorectomy before natural menopause compared to women who had natural menopause at equivalent ages:[1][2]

Cardiovascular disease. Premature loss of estrogen's cardiovascular protection is more severe with abrupt withdrawal than with gradual decline. Women who had bilateral oophorectomy before 45 have significantly higher rates of cardiovascular disease and cardiovascular mortality.

Cognitive decline and dementia. The brain is highly estrogen-sensitive. Prolonged estrogen deprivation beginning in younger years is associated with increased risk of cognitive impairment and dementia. Multiple studies find that the earlier the oophorectomy and the longer the subsequent estrogen deprivation, the greater the cognitive risk.[2]

Bone density. Accelerated bone loss begins immediately after surgical menopause rather than over several years, and starts from a younger baseline.

Metabolic health. Increased rates of metabolic syndrome, insulin resistance, and obesity have been documented following bilateral oophorectomy, consistent with estrogen's role in metabolic regulation.

Neurological conditions. Some observational data have associated early bilateral oophorectomy with increased risk of Parkinson's disease, though the mechanism is not established.

Why HRT Is More Strongly Indicated

For natural menopause, HRT is guided by symptom burden and individual risk-benefit assessment. For surgical menopause in premenopausal women, the framing shifts. Withholding HRT from a surgically menopausal woman under 45 means leaving her with accelerated cardiovascular, bone, and cognitive risk at an age when her natural peers still have full ovarian function.

The North American Menopause Society recommends that women who undergo surgical menopause before age 45 should start hormone therapy, and that it should be maintained at least until the average age of natural menopause (approximately 51) if well tolerated.[3] The purpose is not comfort management; it is health risk mitigation.

NICE guidance and the British Menopause Society reach the same conclusion: in women who have bilateral oophorectomy before natural menopause, the risk of withholding HRT exceeds the risk of using it.

What HRT for Surgical Menopause Looks Like

Because the ovaries produced not only estrogen and progesterone but also testosterone, surgical menopause creates androgen deficiency alongside estrogen deficiency. This differs from natural menopause, where the adrenal glands continue producing a proportion of androgens after ovarian function ceases.

The preferred formulation is transdermal estradiol at an adequate dose, combined with micronized progesterone for women who still have a uterus. The dose required to manage symptoms and mitigate health risk in surgical menopause is often higher than standard postmenopausal doses, reflecting the more complete estrogen deficiency.[3]

Testosterone therapy is also relevant, particularly for sexual desire and energy. Given the complete loss of ovarian testosterone production, the indication is clearer in surgical than in natural menopause. Transdermal testosterone at physiological female doses has evidence for hypoactive sexual desire disorder.

For Women With BRCA Mutations

Risk-reducing salpingo-oophorectomy (RRSO) is recommended for BRCA1 and BRCA2 mutation carriers to reduce ovarian and fallopian tube cancer risk. The timing is driven by cancer risk, not hormonal preference.

For BRCA1 carriers, RRSO is typically recommended between ages 35 and 40. The resulting decades of estrogen deficiency carry substantial long-term health risk. Research in BRCA mutation carriers who undergo RRSO finds that HRT does not increase breast cancer risk in this population (bilateral oophorectomy itself dramatically reduces it), and that HRT restores many of the health risks introduced by the surgery.[4]

Women who have had RRSO for BRCA should discuss HRT with both their gynaecologist and oncologist. The evidence supports its use until at least the age of natural menopause in most BRCA mutation carriers who have not had breast cancer.

References

[1] Parker, W. H., Feskanich, D., Broder, M. S., et al. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstetrics and Gynecology, 121(4), 709-716. See also: Surgical menopause risks overview. https://pmc.ncbi.nlm.nih.gov/articles/PMC7614764/

[2] Rocca, W. A., Bower, J. H., Maraganore, D. M., et al. (2007). Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology, 69(11), 1074-1083. See also: Maintaining cognitive function in surgically menopausal women. https://pmc.ncbi.nlm.nih.gov/articles/PMC8118141/

[3] The Menopause Society (NAMS). Position statement on hormone therapy in women with premature ovarian insufficiency and surgical menopause. See also: Long-term non-cancer risks following RRSO and the role of HRT. https://pmc.ncbi.nlm.nih.gov/articles/PMC9913268/

[4] Marchetti, C., De Felice, F., Boccia, S., et al. (2018). Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Critical Reviews in Oncology/Hematology, 132, 111-115. https://doi.org/10.1016/j.critrevonc.2018.09.018